Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat plus dapagliflozin for prevention of incident heart failure and cardiovascular death in high-risk adults
2024-514506-32-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Planned start May 2025; status: authorised.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2024-514506-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514506-32-00.